The Mustang Bio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, Data-Driven rating system and does not include human intervention.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.
What was Mustang Bio’s price range in the past 12 months?
Mustang Bio lowest stock price was $2.42 and its highest was $5.22 in the past 12 months.
What is Mustang Bio’s market cap?
Mustang Bio’s market cap is $295.99M.
What is Mustang Bio’s price target?
The average price target for Mustang Bio is $10.33. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $13.00 ,the lowest forecast is $7.00. The average price target represents 204.72% Increase from the current price of $3.39.
What do analysts say about Mustang Bio?
Mustang Bio’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
When is Mustang Bio’s upcoming earnings report date?
Mustang Bio’s upcoming earnings report date is Aug 16, 2021 which is next month.
How were Mustang Bio’s earnings last quarter?
Mustang Bio released its earnings results on May 14, 2021. The company reported -$0.186 earnings per share for the quarter, beating the consensus estimate of -$0.187 by $0.001.
Is Mustang Bio overvalued?
According to Wall Street analysts Mustang Bio’s price is currently Undervalued.
Does Mustang Bio pay dividends?
Mustang Bio does not currently pay dividends.
What is Mustang Bio’s EPS estimate?
Mustang Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mustang Bio have?
Mustang Bio has 87,310,000 shares outstanding.
What happened to Mustang Bio’s price movement after its last earnings report?
Mustang Bio reported an EPS of -$0.186 in its last earnings report, beating expectations of -$0.187. Following the earnings report the stock price went up 5.926%.
Which hedge fund is a major shareholder of Mustang Bio?
Among the largest hedge funds holding Mustang Bio’s share is Consonance Capital. It holds Mustang Bio’s shares valued at N/A.